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The purpose of this study was to evaluate prognostic factors for epithelial ovarian cancer.  We found 
that the pretreatment values of maximum standardized uptake (SUVmax) of the primary tumor by 
positron emission tomography/computed tomography (PET/CT),  tumor marker CA125 and C-reactive 
protein (CRP) were correlated with clinical characteristics and prognosis for such patients.  The clini-
cal parameters and prognoses and their correlations with SUVmax of primary tumor,  CA125 and CRP 
were examined for 51 patients with primary ovarian cancer.  The SUVmax of the primary tumor had 
a statistically signiﬁcant association with stage (p＝0.010) and histology (p＝0.001).  CA125 was signiﬁ-
cant associated with stage (p＝0. 011),  histology (p＝0.005) and lymph node metastasis (p＝0.025).  CRP 
was also signiﬁcantly associated with stage (p＝0.049).  Disease-free survival rates of patients exhibit-
ing a high SUVmax,  CA125 and CRP were signiﬁcantly lower than those exhibiting a low SUVmax,  
CA125 and CRP levels (p＝0.008,  0.034,  and 0.037,  respectively).  Furthermore,  overall survival rates 
of patients exhibiting a high SUVmax were signiﬁcantly lower than those exhibiting a low SUVmax (p
＝0.049). The high SUVmax of primary tumor is an important factor for identifying ovarian cancer 
patients with a predictor for poor prognosis.
Key words: ovarian cancer,  SUVmax of primary tumor,  CA125,  C-reactive protein,  predictor for poor 
prognosis
varian cancer is the second most common gyne-
cological malignancy in the United States,  
accounting for about 21,500 new cases of cancer and 
14,600 deaths in the United States in 2009 [1].  
Every year in Japan,  8,000 cases of ovarian cancer are 
newly diagnosed and more than 4,000 women die of the 
disease [2].  Five-year survival rates are inversely 
related to the stage of the disease at ﬁrst diagnosis.  
The 5-year survival rate for stage I disease is 92.7ｵ.  
The majority of cases (67-74ｵ),  however,  are diag-
nosed with metastatic disease (stage III-IV),  which has 
a 5-year survival rate of only 30.6ｵ [3].
　 Imaging has become a signiﬁcant part of the clinical 
management of patients with ovarian cancer.  It is 
important for tumor detection,  staging,  and treatment 
planning.  Imaging ﬁndings help physicians and oncolo-
gists create a speciﬁc treatment plan for each indi-
vidual patient [4].  Metabolic imaging with 18F-FDG 
PET/CT is a well-established method for the evalua-
tion of primary tumors at the initial,  pretreatment 
stage.  PET/CT is superior to CT and MRI for diag-
nosis of ovarian cancer [5].  In current practice,  
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examination of the maximum standardized uptake 
value (SUVmax) of 18F-FDG PET/CT is one of the 
most common methods to evaluate primary tumors for 
the likely clinical outcome.  The SUVmax is a unique,  
noninvasive marker for studying biochemical and 
metastatic changes in cancer tissues.  The SUVmax 
has been correlated with tumor proliferation rates,  
tumor grade and expression of glucose transporters,  
all of which are biomarkers in various types of malig-
nant tumors [6].
　 A well-characterized biomarker for ovarian cancer 
is CA125 [7].  Serum CA125 is elevated (i.e.＞35U/
ml) in more than 90ｵ of patients with late-stage dis-
ease [8].  Its kinetics during chemotherapy has value 
in predicting residual disease and survival,  and levels 
after therapy can predict recurrence [9].  CA125 
levels at clinical presentation are lower in women with 
mucinous tumors and correlate directly with the stage 
of disease and inversely with survival [10].
　 C-reactive protein (CRP) is an acute reactant 
protein that is increased under various conditions of 
infection,  trauma,  tissue necrosis,  tumor,  and several 
types of inﬂammatory disease.  Many cancers arise 
from sites of infection,  chronic irritation and inﬂam-
mation [11].  Evidently,  tumor cells co-opt some of 
the signaling molecules of the innate immune system,  
such as selectins,  chemokines and their receptors for 
invasion,  migration and metastasis [12].  Serum CRP 
has been investigated as a risk factor and prognostic 
variable in various human malignancies [13].
　 It remains uncertain whether the SUVmax of the 
primary tumor,  CA125 and/or CRP are appropriate 
for predicting outcomes in ovarian cancer.  In this 
study,  we evaluated whether pretreatment values of 
SUVmax of the primary tumor,  serum CA125 and 
serum CRP could serve as prognostic indicators in 
patients with epithelial ovarian cancer.
Materials and methods
　 Patients. Fifty-one patients with epithelial 
ovarian cancer were referred for treatment to the 
Department of Obstetrics and Gynecology of Okayama 
University Hospital between April 2007 and Septem-
ber 2010.  They underwent PET/CT prior to treat-
ment as part of their initial clinical evaluation.  Cancers 
were staged according to the FIGO staging system,  
and the local extent of disease was diagrammed on a 
tumor staging form.  The distribution of clinical stages 
was as follows: 5 stage Ia cancers; 12 stage Ic can-
cers; 1 stage IIa cancer; 1 stage IIb cancer; 3 stage 
IIc cancers; 2 stage IIIb cancers; 23 stage IIIC can-
cers; and 4 stage IV cancers.  The histological cell 
types were classiﬁed according to the WHO classiﬁca-
tion as follows: 29 serous adenocarcinomas; 11 clear 
cell carcinomas; 4 endometrioid adenocarcinomas; 4 
mucinous adenocarcinomas; and 3 mixed type carcino-
mas (2 serous＋endometrioid adenocarcinoma,  and 1 
mucinous adenocarcinoma＋squamous cell carcinoma).  
Early stage (stage I-II) ovarian cancer patients (n＝
22) underwent maximal pelvic/abdominal debulking 
surgery followed by chemotherapy with carboplatin 
(Bristol-Myers Squibb,  NY,  USA) and taxol (Bristol-
Myers Squibb,  NY,  USA).  Late-stage (stage III-IV) 
ovarian cancer patients underwent primary debulking 
surgery (PDS) (n＝11) and interval debulking surgery 
(IDS) (n＝18).  Patients who underwent PDS or 
maximal pelvic/abdominal debulking surgery were then 
treated with six to nine sets of standard chemother-
apy.  This included 3 to 5 cycles of neoadjuvant che-
motherapy with IDS followed by at least 3 cycles of 
adjuvant chemotherapy.  The mean age at the time of 
treatment was 60.3 years (range,  31-83 years).
　 PET/CT technique and image analysis. A 
total of 51 women underwent PET/CT prior to treat-
ment between April 2007 and September 2010 at the 
Okayama Diagnostic Imaging Center.  All patients 
fasted for at least 5h before the PET/CT studies.  
Serum glucose levels measured at the time of 18F-
FDG injections were less than 150mg/dL in all 
patients.  18F-FDG (3.7MBq/kg body weight) was 
administered intravenously into the arm,  and the 
patient was then seated on a chair to rest for 90min 
for uptake while drinking 350ml of mineral water for 
hydration.  A whole body PET/CT scan from the 
upper end of the orbit to the femoral region was per-
formed 90min after 18F-FDG administration in the 
supine position with elevation of the bilateral upper 
limbs and consisted of 7 to 8 bed positions with 
2.4min per table position.  Urinary tract activities 
were minimized by the placement of a Foley catheter 
before injection of 18F-FDG and by administration of 
furosemide and i. v.  ﬂuids after injection of 18F-FDG 
in patients.  Images were obtained using a 16-detector 
row helical PET/CT scanner (Biograph LS/sensa-
tion 16,  Siemens,  Munich,  Germany),  and were 
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scatter-corrected and reconstructed using an ordered-
subset expectation-maximization (OSEM) iterative 
reconstruction algorithm with a post-reconstruction 
Gaussian ﬁlter (3mm full width half maximum).  
Three-mm-thick sections were obtained from the base 
of the skull through the proximal thighs at 140kV,  
with 12 to 40m for attenuation data collection and 
diagnosis.
　 Image analysis was performed as follows: attenua-
tion-corrected PET images,  CT images and co-regis-
tered PET/CT images were displayed together on the 
monitor.  The readers had access to all clinical infor-
mation but were unaware of results from other imag-
ing studies.  We also measured the maximum axial 
diameter (deﬁned as size diagnosis) and SUVmax 
(deﬁned as SUV diagnosis) of all parenchymatous 
metastases,  lymph node metastases and disseminations 
with greater FDG uptake than normal organs or sur-
rounding tissue on the FDG-PET/CT images.  The 
cutoﬀ value of SUVmax was the value at which the 
accuracy was the highest.  Size limitations are present 
since implants ＜5mm are inconsistently identiﬁed 
owing to low tracer concentration and limited spatial 
resolution [14].  In this case,  a short-axis diameter of 
over 5mm with positive FDG uptake (SUVmax ｧ3.0) 
on PET/CT was considered to be a metastasis.  The 
CT attenuation data were semiquantitatively measured 
using SUVmax,  which was normalized using the lean 
body mass.  For the measurement of FDG uptake,  
regions of interest (ROI) were manually placed on the 
main ovary lesion and parenchymatous metastasis,  
lymph node metastasis and disseminations when abnor-
mal uptakes were observed.  SUV was calculated using 
the following formula:
SUV＝A/(B/C),
where A is the radioactivity concentration in the ROI 
(in becquerels),  B is the injected dose of FDG (in 
becquerels),  and C is the body weight (in grams).  The 
SUVmax is the maximum SUV.  The images were 
evaluated by 2 nuclear-medicine physicians informed 
about the clinical data of the patient at the time of the 
scan.  Diﬀerences in the measurements by the 2 nuclear 
medicine physicians are not shown.
　 CA125 and CRP assays. The assays for 
CA125 and CRP were carried out at the clinical 
chemistry laboratory at Okayama University Hospital 
prior to surgery or chemotherapy.  The upper limit of 
normal was 35U/ml for CA125 and 0.3mg/dl for 
CRP.
　 Statistical analysis. Statistical analyses were 
performed using the Mann-Whitney U-test for com-
parisons with the controls and one-factor ANOVA 
followed by Fisherʼs protected least signiﬁcance dif-
ference test for all pairwise comparisons.  The survival 
rates were calculated by the Kaplan-Meier method,  
and the diﬀerences between the survival curves were 
examined by the log-rank test.  Analyses were per-
formed using the software package StatView version 
5.0 (Abacus Concepts,  Berkeley,  CA,  USA).  Diﬀer-
ences were considered signiﬁcant at p＜0.05.
Results
　 In this study,  we assessed the association between 
the pretreatment values of SUVmax of the primary 
tumor,  CA125,  CRP,  and the clinical parameters and 
outcomes of ovarian cancers.  Fifty-one patients under-
went pretreatment assessment of serum CA125 and 
serum CRP as well as pretreatment imaging.  The 
mean SUVmax on pretreatment imaging of the primary 
ovarian cancer in the 51 patients was 13.15,  with a 
range of 3.0-28.1.  The mean serum CA125 was 
1052.24U/ml,  with a range of 17.0-7153U/ml.  The 
mean serum CRP was 1.67mg/dl,  with a range of 
0.01-11.77mg/dl.
　 Table 1 shows the distribution of scores for each 
of the biological parameters examined according to the 
clinical characteristics in the study population.  The 
SUVmax of the primary tumor showed a statistically 
signiﬁcant association with FIGO stage (p＝0.010) 
and histology (p＝0.001).  CA125 was signiﬁcant 
associated with FIGO stage (p＝0.011),  histology (p
＝0.005) and lymph node metastasis (p＝0.025).  CRP 
was also signiﬁcant associated with FIGO stage (p＝
0.049).  We assessed the association between SUV max 
of primary tumor,  CA125,  CRP and both FIGO stage 
and tumor histology.  However,  there was no correla-
tion of the SUVmax of the primary tumor,  CA125,  or 
CRP with FIGO stage or histology on ovarian cancer 
(data not shown).
　 Late-stage disease (stage III and IV) and serous 
adenocarcinoma were signiﬁcantly more frequently 
associated than early-stage disease and lack of serous 
adenocarcinoma with high values of SUVmax of pri-
mary tumor,  CA125,  and CRP (p＜0.005,  p＜0.005,  
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and p＜0.05) (Fig.  1A).  However,  there was no cor-
relation found between the SUVmax of the primary 
tumor and serum CA125,  between the SUVmax of the 
primary tumor and serum CRP,  or between serum 
CA125 and CRP of primary ovarian cancer (R＝
0.155,  0.199,  0.253) (Fig.  1B).
　 The mean duration of follow-up was 11.4 months 
(range,  1-38 months).  At the time of the last follow-
up,  33 patients were alive with no evidence of dis-
ease,  8 patients had died of disease,  and 10 patients 
were alive with disease.  The mean duration of sur-
vival was 14.9 months (range,  1-38 months).  Fig.  2 
shows the disease-free and overall survival curves of 
the 51 ovarian cancer patients in relation to the pre-
treatment SUVmax of the primary tumor,  serum 
CA125,  and serum CRP.  We divided the pretreat-
ment SUVmax,  CA125,  and CRP values into high and 
low groups using the mean values as cut-oﬀs: 13.15,  
1052.24 (U/ml),  and 1.67 (mg/dl),  respectively.  The 
disease-free survival rates of patients exhibiting high 
SUVmax of the primary tumor,  CA125 and CRP 
were signiﬁcantly worse than those of patients exhibit-
ing low SUVmax of the primary tumor,  CA125 and 
CRP (p＝0.008,  0.034,  and 0.037).  Moreover,  the 
overall survival rate of ovarian cancer patients exhib-
iting a high SUVmax of the primary tumor was statis-
tically signiﬁcantly worse (p＝0.049).  However,  high 
serum CA125 and CRP were not associated with a 
diagnosis of a good overall survival rate for the ovar-
ian cancer patient.
Discussion
　 The pretreatment stage,  tumor size,  and lymph 
node status have been recognized as important predic-
tors of patient survival in all cancers.  It is accepted 
that new approaches to ovarian cancers are pivotal in 
improving treatment of this disease.  This is the ﬁrst 
study to evaluate the association between the pretreat-
ment SUVmax of primary tumors,  serum CA125,  
serum CRP and clinical factors and prognosis in 
patients with primary epithelial ovarian cancer.
　 The presence of abnormal FDG uptake on 18F-
FDG PET/CT images has been widely accepted as a 
criterion for diﬀerentiation between benign and malig-
nant disease in various cancers.  FDG uptake has been 
evaluated mainly by visual inspection or calculation of 
the SUV.  A high SUVmax has been shown to corre-
late with tumor proliferation and with other signs of 
aggressive tumor behavior including risk of metastasis 
[15].  Several studies have reported that the SUVmax 
of the primary tumor is associated with the clinical 
stage,  tumor grade,  cell proliferation,  and/or glu-
cose metabolism,  all of which are reported to be bio-
markers for response to chemotherapy and prognosis 
in ovarian cancer [16,  17].
　 The serum tumor marker CA125 is used for initial 
diagnosis and monitoring of response to chemotherapy 
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Table 1　 Association between SUVmax of primary tumor,  CA125,  CRP and clinical characteristics of ovarian cancer
Variable Cases SUVmax(mean±SE) p-value
＊ CA-125
(mean±SE) p-value
＊ CRP p-value＊
Age (years) 0.729　 0.259　 0.502　
＜60 28 12.90±6.02 815.41±994.77 1.42±2.36
ｧ60 23 13.45±4.84 1340.56±2000.00 1.95±3.13
FIGO stage 0.010＊ 0.011＊ 0.049＊
I＋ II 22 10.52±4.98 428.07±813.54 1.08±2.11
III＋ IV 29 15.15±5.03 1525.75±1785.19 2.12±3.07
Histology 0.001＊ 0.005＊ 0.158　
Non serous 22 10.94±4.80 482.05±803.63 0.91±1.53
Serous 29 14.83±5.43 1484.8±1813.28 2.24±3.26
Lymph node metastasis 0.147　 0.025＊ 0.114　
Negative 35 12.35±5.80 611.74±964.07 1.16±2.21
Positive 16 14.76±4.47 1933.25±2057.65 2.68±3.37
＊Mann-Whitney U-test.  FIGO,  International Federation of Gynecology and Obstetrics.
Lymph node status was assessed by PET/CT imaging in 18 patients.
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＊p＜0.005
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1. Stage I-II (Non serous adenocarcinoma) (n=18) 2. Stage I-II (Serous adenocarcinoma)(n=4)
3. Stage III-IV (Non serous adenocarcinoma)(n=4) 4. Stage III-IV (Serous adenocarcinoma)(n=25)
0
10
20
30
1. 2. 3. 4.
＊
SUVmaxA CA125
0
2,000
4,000
6,000
8,000
4.1. 2. 3.
U/ml ＊
CRP
0
3
6
9
12
15
＊＊
1. 2. 3. 4.
mg/dl
SUVmax and CA125
R=0.155
B
CA125 (U/ml)
-1,000 1,000 3,000 5,000 7,000
30
20
10
0
SU
Vm
ax
SUVmax and CRP
R=0.199
CRP (mg/dl)
0 2 4 6 8 10 12 14
30
20
10
0
SU
Vm
ax
CRP (mg/dl)
R=0.253
C
A1
25
 (U
/m
l)
CA125 and CRP
0 2 4 6 8 10 12 14
8,000
6,000
4,000
2,000
0
Fig. 1　 A,  Histogram of the SUVmax of the primary tumor,  CA125,  and CRP expression levels by each stage and histology (1) Early 
stage (stage I-II) (Non serous adenocarcinoma) (n＝18); (2) Early stage (stage I-II) (Serous adenocarcinoma) (n＝4); (3) Late-stage 
(stage III-IV) (Non serous adenocarcinoma) (n＝4); (4) Late-stage (stage III-IV) (Serous adenocarcinoma) (n＝25).  B,  Regression analy-
sis of SUVmax of the primary tumor and serum CA125,  SUVmax of the primary tumor and serum CRP,  serum CA125 and CRP from 51 
patients with pretreatment of primary ovarian cancer.
for epithelial ovarian cancer.  Regular measurement 
during follow-up is one of the best examples in oncol-
ogy of a test that can detect recurrence of cancer 
months before symptoms or signs occur [18].
　 Serum CRP was independently associated with 
overall survival.  This ﬁnding is in accordance with 
other inﬂammation-related cytokines,  such as vascular 
endothelial growth factor and interleukin-6 [19,  20].  
Heﬂer and colleagues have reported that ovarian can-
cer patients with a low (ｦ1mg/dL) serum CRP had 
signiﬁcantly better prognoses than those with an ele-
vated (＞1mg/dL) serum CRP [21].
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Fig. 2　 Kaplan-Meier plots for the disease-free survival and overall survival rates of the 51 patients with pretreatment of primary ovarian 
cancer according to their SUVmax of primary tumor,  serum CA125 or serum CRP.  A,  SUVmax of primary tumor (＜13.15) (n＝26); B,  
SUVmax of primary tumor (ｧ13.15) (n＝25); C,  Serum CA125 (＜1052.24U/ml) (n＝35); D,  Serum CA125 (ｧ1052.24U/ml) (n＝
16); E,  Serum CRP (＜1.67mg/dl) (n＝36); F,  Serum CRP (ｧ1.67mg/dl) (n＝15).
　 However,  there has been no report in which pre-
treatment SUVmax of primary tumors and serum 
biomarkers were measured and correlated with clini-
copathological characteristics and prognoses in 
patients with ovarian cancer.  We found that the pre-
treatment SUVmax of the primary tumor in ovarian 
cancer patients showed a statistically signiﬁcant asso-
ciation with FIGO stage and histology.  The pretreat-
ment CA125 level was also signiﬁcantly associated 
with FIGO stage,  histology and lymph node metasta-
sis.  CRP was signiﬁcantly associated only with FIGO 
stage (Table 1).  Furthermore,  the present study 
revealed signiﬁcantly greater associations of high 
values for pretreatment SUVmax of the primary 
tumor,  CA125 and CRP with late-stage disease 
(Stage III or IV) and serous adenocarcinoma than with 
early-stage disease and non-serous adenocarcinoma 
(Fig.  1A).  However,  there was no correlation noted 
between the pretreatment values of SUVmax of the 
primary tumor and serum CA125,  between SUVmax 
of the primary tumor and serum CRP,  or between 
serum CA125 and CRP in primary ovarian cancer 
(Fig.  1B).  These were each independent risk factors 
for ovarian cancer.
　 This is the ﬁrst report to associate pretreatment 
values of SUVmax of the primary tumor,  CA125 and 
CRP with the prognosis of ovarian cancer patients.  
The high/low cut-oﬀ values for SUVmax,  CA125,  
and CRP,  as determined by the means,  were 13.15,  
1052.24 (U/ml),  and 1.67 (mg/dl).  The disease-free 
survival rates of patients exhibiting high pretreatment 
values for SUVmax of primary tumor,  CA125 and 
CRP were signiﬁcantly lower than those of patients 
with low SUVmax of the primary tumor,  CA125 and 
CRP for ovarian cancer.  Moreover,  the overall sur-
vival rates of ovarian cancer patients exhibiting high 
and low SUVmax values of the primary tumor were 
signiﬁcantly diﬀerent (Fig.  2).  Taken together,  these 
ﬁndings indicate that a high SUVmax of the primary 
tumor is an important factor for identifying ovarian 
cancer patients with a poor prognosis.
　 We acknowledge that there are several limitations 
to our study.  First,  the number of patients was rela-
tively small.  Second,  the duration of follow-up and 
survival was relatively short.  A larger number of 
patients and longer-term follow-up would improve the 
quality of our data,  and further conﬁrmation by a 
prospective trial could reinforce our ﬁndings.
　 In summary,  there is good evidence that 18F-FDG 
PET/CT can be useful for the pretreatment assess-
ment of ovarian cancer.  We here report our ﬁndings 
that a high (＞13.15) pretreatment SUVmax of the 
primary tumor in patients with ovarian cancer was 
associated with a poor prognosis.
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